EE390 Optimizing the Use of Risk Factors to Guide the Cost-Effective Use of Palivizumab Prophylaxis Against Severe Respiratory Syncytial Virus Infection in Korean Infants Born 32–35 Weeks' Gestational Age.

Authors :: Keary, I.
Kang, J.M.
Paes, B.
Rodgers-Gray, B.
Fullarton, J.
Tarride, J.E.
Yang, H.J.
Chang, Y.S.
Carbonell-Estrany, X.
Source :: Value in Health. 2023 Supplement, Vol. 26 Issue 12, pS125-S125. 1p.
Publication Year :: 2023

Subjects :: *RESPIRATORY syncytial virus infections
*GESTATIONAL age
*PALIVIZUMAB
*INFANTS
*PREVENTIVE medicine

Full Text Access

Tools